NASDAQ
TBPH

Theravance Biopharma Inc

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Theravance Biopharma Inc Stock Price

Vitals

Today's Low:
$9.6350
Today's High:
$9.9700
Open Price:
$9.9700
52W Low:
$7.53
52W High:
$13.17
Prev. Close:
$9.9700
Volume:
787355

Company Statistics

Market Cap.:
$0.644 billion
Book Value:
-2.423
Revenue TTM:
$0.052 billion
Operating Margin TTM:
-265.4%
Gross Profit TTM:
$-0.138 billion
Gross Profit TTM:
$-0.138 billion
Profit Margin:
-193.7%
Return on Assets TTM:
-22%
Return on Equity TTM:
0%

Company Profile

Theravance Biopharma Inc had its IPO on 2014-05-16 under the ticker symbol TBPH.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Theravance Biopharma Inc has a staff strength of 0 employees.

Stock update

Shares of Theravance Biopharma Inc opened at $9.97 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $9.64 - $9.97, and closed at $9.65.

This is a -3.21% slip from the previous day's closing price.

A total volume of 787,355 shares were traded at the close of the day’s session.

In the last one week, shares of Theravance Biopharma Inc have slipped by -3.5%.

Theravance Biopharma Inc's Key Ratios

Theravance Biopharma Inc has a market cap of $0.644 billion, indicating a price to book ratio of - and a price to sales ratio of 12.3.

In the last 12-months Theravance Biopharma Inc’s revenue was $0.052 billion with a gross profit of $-0.138 billion and an EBITDA of $-0.134 billion. The EBITDA ratio measures Theravance Biopharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Theravance Biopharma Inc’s operating margin was -265.4% while its return on assets stood at -22% with a return of equity of 0%.

In Q2, Theravance Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 14.4%.

Theravance Biopharma Inc’s PE and PEG Ratio

Forward PE
7.18
Trailing PE
-
PEG
-0.05

Its diluted EPS in the last 12-months stands at $-2.019 per share while it has a forward price to earnings multiple of 7.18 and a PEG multiple of -0.05. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Theravance Biopharma Inc’s profitability.

Theravance Biopharma Inc stock is trading at a EV to sales ratio of 23.14 and a EV to EBITDA ratio of -26.65. Its price to sales ratio in the trailing 12-months stood at 12.3.

Theravance Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Theravance Biopharma Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Theravance Biopharma Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Theravance Biopharma Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Theravance Biopharma Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Theravance Biopharma Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$9.65
52-Week High
$13.17
52-Week Low
$7.53
Analyst Target Price
$10.57

Theravance Biopharma Inc stock is currently trading at $9.65 per share. It touched a 52-week high of $13.17 and a 52-week low of $13.17. Analysts tracking the stock have a 12-month average target price of $10.57.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Theravance Biopharma Inc

The stock symbol (also called stock or share ticker) of Theravance Biopharma Inc is TBPH

The IPO of Theravance Biopharma Inc took place on 2014-05-16

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$3
0.1
+3.45%
$2.51
0.06
+2.45%
$0.89
-0.07
-6.97%
$0.32
-0
-0.19%
$0.33
0.01
+3.63%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.

Address

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, KY